دورية أكاديمية
أعرض في EDS

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.

التفاصيل البيبلوغرافية
العنوان: Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.
المؤلفون: Kapadia B; Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA., Nanaji NM; Department of Veteran Affairs, Maryland Healthcare System, Baltimore, MD 21201, USA.; University of Maryland Medical Center, Baltimore, MD, 21201, USA., Bhalla K; Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA., Bhandary B; Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA., Lapidus R; Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA., Beheshti A; Division of Hematology/Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA, 02111, USA., Evens AM; Division of Hematology/Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA, 02111, USA., Gartenhaus RB; Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA. rgartenhaus@som.umaryland.edu.; Veterans Administration Medical Center, Baltimore, MD, 21201, USA. rgartenhaus@som.umaryland.edu.
المصدر: Nature communications [Nat Commun] 2018 Feb 26; Vol. 9 (1), pp. 829. Date of Electronic Publication: 2018 Feb 26.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic* , Protein Biosynthesis*, Eukaryotic Initiation Factors/*genetics , Fatty Acid Synthase, Type I/*genetics , Ribosomal Protein S6 Kinases/*genetics , Thiolester Hydrolases/*genetics, Animals ; B-Lymphocytes/metabolism ; B-Lymphocytes/pathology ; Carcinogenesis/genetics ; Carcinogenesis/metabolism ; Carcinogenesis/pathology ; Cell Line, Tumor ; Eukaryotic Initiation Factors/metabolism ; Fatty Acid Synthase, Type I/metabolism ; Female ; Humans ; Lipid Metabolism/genetics ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Lymphoma, Large B-Cell, Diffuse/pathology ; Mice ; Mice, Nude ; Neoplasm Transplantation ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphorylation ; Protein Binding ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Ribosomal Protein S6 Kinases/metabolism ; Signal Transduction ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Thiolester Hydrolases/metabolism
مستخلص: Altered lipid metabolism and aberrant protein translation are strongly associated with cancerous outgrowth; however, the inter-regulation of these key processes is still underexplored in diffuse large B-cell lymphoma (DLBCL). Although fatty acid synthase (FASN) activity is reported to positively correlate with PI3K-Akt-mTOR pathway that can modulate protein synthesis, the precise impact of FASN inhibition on this process is still unknown. Herein, we demonstrate that attenuating FASN expression or its activity significantly reduces eIF4B (eukaryotic initiation factor 4B) levels and consequently overall protein translation. Through biochemical studies, we identified eIF4B as a bonafide substrate of USP11, which stabilizes and enhances eIF4B activity. Employing both pharmacological and genetic approaches, we establish that FASN-induced PI3K-S6Kinase signaling phosphorylates USP11 enhancing its interaction with eIF4B and thereby promoting oncogenic translation.
References: PLoS Pathog. 2014 May 22;10(5):e1004163. (PMID: 24852294)
BMC Evol Biol. 2015 Oct 26;15:230. (PMID: 26503449)
Leukemia. 2014 May;28(5):1092-102. (PMID: 24135829)
Blood. 2009 Sep 17;114(12 ):2467-75. (PMID: 19608751)
J Exp Med. 2006 Feb 20;203(2):311-7. (PMID: 16492805)
Curr Opin Hematol. 2014 Jul;21(4):341-9. (PMID: 24811161)
J Biol Chem. 2006 Jul 28;281(30):20788-800. (PMID: 16720573)
Mol Cell Biol. 2014 Jul;34(13):2517-32. (PMID: 24777602)
Cancer Res. 2008 Feb 15;68(4):1003-11. (PMID: 18281474)
Mol Cell Biol. 2013 Mar;33(6):1188-97. (PMID: 23297343)
Mol Cancer Ther. 2010 May;9(5):1244-55. (PMID: 20423996)
Cell. 2009 Jul 23;138(2):389-403. (PMID: 19615732)
Biochem Soc Trans. 2016 Dec 15;44(6):1667-1673. (PMID: 27913676)
Cell Cycle. 2012 Mar 15;11(6):1123-30. (PMID: 22370483)
Nat Methods. 2012 Sep;9(9):907-9. (PMID: 22863883)
Mol Cell Biol. 2004 Sep;24(17):7444-55. (PMID: 15314155)
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. (PMID: 16341064)
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9810-5. (PMID: 27528663)
Cell Cycle. 2010 Oct 15;9(20):4106-9. (PMID: 20948310)
Cancer Cell. 2017 Jan 9;31(1):64-78. (PMID: 28073005)
Oncotarget. 2017 Feb 14;8(7):11600-11613. (PMID: 28086243)
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420-5. (PMID: 23840064)
Nat Rev Cancer. 2016 Nov;16(11):732-749. (PMID: 27658529)
Blood. 2010 Mar 18;115(11):2127-35. (PMID: 20075156)
Blood. 2014 Dec 11;124(25):3758-67. (PMID: 25320244)
Cold Spring Harb Perspect Med. 2013 Aug 01;3(8):null. (PMID: 23906881)
Blood Cancer J. 2013 Jul 19;3:e128. (PMID: 23872707)
Oncotarget. 2013 Jan;4(1):35-47. (PMID: 23296022)
J Hematol Oncol. 2017 Mar 17;10 (1):70. (PMID: 28302137)
Leuk Lymphoma. 2010 Oct;51(10):1805-15. (PMID: 20629523)
Lab Invest. 2016 Sep;96(9):1004-15. (PMID: 27501049)
J Exp Med. 2015 May 4;212(5):775-92. (PMID: 25847947)
Blood. 2011 Feb 24;117(8):2441-50. (PMID: 21209379)
Oncotarget. 2015 Oct 27;6(33):34992-5003. (PMID: 26378037)
Cell Signal. 2010 Mar;22(3):386-94. (PMID: 19874889)
Breast Cancer Res Treat. 2004 Mar;84(2):183-95. (PMID: 14999148)
Breast Cancer Res Treat. 2014 Sep;147(2):283-93. (PMID: 25129346)
Cancer Cell. 2010 Dec 14;18(6):568-79. (PMID: 21156281)
EBioMedicine. 2017 Feb;15:48-61. (PMID: 28040451)
Curr Pharm Des. 2013;19(18):3175-89. (PMID: 23151131)
Genetics. 2005 Dec;171(4):1629-41. (PMID: 15972466)
Am J Pathol. 2014 Jan;184(1):4-17. (PMID: 24139946)
EMBO J. 2010 Aug 4;29(15):2553-65. (PMID: 20601937)
Blood. 2016 Feb 18;127(7):858-68. (PMID: 26603836)
Clin Cancer Res. 2015 Dec 15;21(24):5434-8. (PMID: 26519059)
Am J Cancer Res. 2016 Dec 01;6(12 ):2901-2909. (PMID: 28042509)
PLoS One. 2013;8(2):e56741. (PMID: 23418597)
Nat Methods. 2009 Apr;6(4):275-7. (PMID: 19305406)
Proc Natl Acad Sci U S A. 2016 Oct 24;:. (PMID: 27791122)
Nat Rev Drug Discov. 2015 Apr;14(4):261-78. (PMID: 25743081)
Cancer Res. 2013 Aug 1;73(15):4898-908. (PMID: 23749639)
Cancer Res. 2017 Feb 1;77(3):613-622. (PMID: 27879264)
J Hematop. 2013 Mar;6(1):11-18. (PMID: 25937841)
Nat Commun. 2011 Jul 19;2:402. (PMID: 21772273)
Trends Cancer. 2016 Nov;2(11):688-697. (PMID: 28741507)
Cell. 2015 May 21;161(5):1138-1151. (PMID: 25981667)
Mol Cancer Res. 2013 Aug;11(8):901-11. (PMID: 23696131)
J Biol Chem. 2010 May 7;285(19):14565-71. (PMID: 20233726)
Cancer Manag Res. 2013 Aug 23;5:251-69. (PMID: 24049458)
Pharmacol Ther. 2015 Mar;147:32-54. (PMID: 25444757)
Curr Biol. 2014 Oct 6;24(19):2274-80. (PMID: 25220053)
Nat Commun. 2014;5:3214. (PMID: 24487962)
Cell Death Dis. 2016 Sep 22;7(9):e2371. (PMID: 27899822)
Open Biol. 2012 Jun;2(6):120063. (PMID: 22773947)
Nucleic Acids Res. 2006;34(19):5528-40. (PMID: 17023487)
Oncogenesis. 2016 Jan 25;5:e189. (PMID: 26807644)
معلومات مُعتمدة: I01 BX002990 United States BX BLRD VA; R01 CA164311 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Eukaryotic Initiation Factors)
0 (USP11 protein, human)
0 (eIF-4B)
EC 2.3.1.85 (FASN protein, human)
EC 2.3.1.85 (Fatty Acid Synthase, Type I)
EC 2.7.1.1 (MTOR protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
EC 3.1.2.- (Thiolester Hydrolases)
تواريخ الأحداث: Date Created: 20180228 Date Completed: 20181121 Latest Revision: 20230814
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5827760
DOI: 10.1038/s41467-018-03028-y
PMID: 29483509
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-018-03028-y